Citation Information :
Surya D, Saranya S, Elanchezhiyan S, Gayathripriyadharshini E, Daniel GR, Vennila K. Evaluation of Serum and Salivary Visfatin Prior to and Post-nonsurgical Periodontal Therapy in Periodontally Healthy and Chronic Periodontitis Patients. World J Dent 2023; 14 (3):263-267.
Aims: This study aims to evaluate the visfatin levels in periodontally healthy persons and subjects with chronic periodontitis and their change in levels with regard to nonsurgical periodontal therapy (NSPT).
Materials and methods: A total of 30 individuals with healthy periodontium and 30 patients with chronic periodontitis in the age range of 25–65 years and with normal body mass index (BMI) were selected for the study. Scaling and root planing were done for chronic periodontitis patients and were reviewed after 2 months. Periodontal clinical parameters were noted, and salivary and serum samples were collected and stored during the first visit and review. Visfatin levels in the samples were evaluated using enzyme-linked immunosorbent assay (ELISA).
Results: Chronic periodontitis patients had elevated levels of serum (38.1 ng/mL vs 16.42 ng/mL) and salivary (57.86 ng/mL vs 19.94 ng/mL) visfatin in comparison to healthy controls. In periodontitis patients, serum (38.1 ng/mL to 20.32 ng/mL) and salivary (57.86 ng/mL to 19.62 ng/mL) levels of visfatin were reduced in response to NSPT.
Conclusion: The elevation in serum visfatin and salivary visfatin levels in chronic periodontitis patients and its reduction in response to NSPT makes visfatin a probable disease marker and a potential therapeutic target for assessing treatment efficacy.
Clinical significance: Visfatin, being an adipocytokine, is closely related to the process of inflammation cascade. Its association with periodontal inflammation and health, as seen in the present study, shows that visfatin may be utilized as a marker in the diagnosis of periodontitis and in the evaluation of treatment efficacy.
Kirkwood KL, Cirelli JA, Rogers JE, et al. Novel host response therapeutic approaches to treat periodontal diseases. Periodontol 2000 2007;43:294–315. DOI: 10.1111/j.1600-0757.2006.00166.x
Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003;82(2):82–90. DOI: 10.1177/154405910308200202
Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol 2011;38:60–84. DOI: 10.1111/j.1600-051X.2010.01671.x
Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med 2005;11(8):344–347. DOI: 10.1016/j.molmed.2005.06.010
Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007;178(3):1748–1758. DOI: 10.4049/jimmunol.178.3.1748
Ognjanovic S, Bao S, Yamamoto SY, et al. Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. J Mol Endocrinol 2001;26(2):107–117. DOI: 0.1677/jme.0.0260107
Sandeep S, Velmurugan K, Deepa R, et al. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism 2007;56(4):565–570. DOI: 10.1016/j.metabol.2006.12.005
Pradeep AR, Raghavendra NM, Prasad MV, et al. Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. J Periodontol 2011;82(9):1314–1319. DOI: 10.1902/jop.2011.100690
Mamali I, Roupas ND, Armeni AK, et al. Measurement of salivary resistin, visfatin and adiponectin levels. Peptides 2012;33(1):120–124. DOI: 10.1016/j.peptides.2011.11.007
Jain H, Mulay S. Relationship between periodontitis and systemic diseases: leptin, a new biomarker? Indian J Dent Res 2014;25(5):657–661. DOI: 10.4103/0970-9290.147118
Devanoorkar A, Kathariya R, Guttiganur N, et al. Resistin: a potential biomarker for periodontitis influenced diabetes mellitus and diabetes induced periodontitis. Dis Markers 2014;2014. DOI: 10.1155/2014/930206
Taşkesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012;4(2):76–81. DOI: 10.4274/jcrpe.547
Bai XJ, Fan LH, He Y, et al. Nicotine may affect the secretion of adipokines leptin, resistin, and visfatin through activation of KATP channel. Nutrition 2016 ;32(6):645–648. DOI: 10.1016/j.nut.2015.12.001
Tabari ZA, Azadmehr A, Nohekhan A, et al. Salivary visfatin concentrations in patients with chronic periodontitis. J Periodontol 2014;85(8):1081–1085. DOI: 10.1902/jop.2013.130388
Özcan E, Saygun NI, Serdar MA, et al. Evaluation of the salivary levels of visfatin, chemerin, and progranulin in periodontal inflammation. Clin Oral Investig 2015;19(4):921–928. DOI: 10.1007/s00784-014-1308-0
Türer ÇC, Balli U, Güven B, et al. Visfatin levels in gingival crevicular fluid and serum before and after nonsurgical treatment for periodontal diseases. J Oral Sci 2016;58(4):491–499. DOI: 10.2334/josnusd.16-0116
Raghavendra NM, Pradeep AR, Kathariya R, et al. Effect of non surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Dis Markers 2012;32(6):383–388. DOI: 10.3233/DMA-2012-0897
Tabari ZA, Ghaedi FB, Azadmehr A, et al. Salivary visfatin concentration in response to nonsurgical periodontal therapy. 2015;9(4):ZC05–ZC08. DOI: 10.7860/JCDR/2015/11537.5773
Abolfazli N, Jabali S, Saleh Saber F, et al. Effect of nonsurgical periodontal therapy on serum and salivary concentrations of visfatin in patients with chronic periodontitis. J Dent Res Dent Clin Dent Prospects 2015;9(1):11–17. DOI: 10.15171/joddd.2015.003
Cekmez F, Canpolat FE, Çetinkaya M, et al. Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis. Eur Cytokine Netw 2011;22(2):113–117. DOI: 10.1684/ecn.2011.0283